Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
FIORINAL W/CODEINE is a combination analgesic containing butalbital, aspirin, caffeine, and codeine phosphate, indicated for tension headaches and similar pain conditions. Delivered as an oral capsule, it combines a barbiturate, NSAID, stimulant, and opioid to provide multi-modal pain relief. The fixed-dose combination targets patients requiring moderate pain control with both tension relief and opioid analgesia.
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely consolidating around retention and managed decline rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on FIORINAL W/CODEINE offers limited career growth due to its LOE-approaching lifecycle and zero linked job postings. Roles on this product are primarily focused on managing market decline, ensuring regulatory compliance, and handling legacy brand stewardship rather than driving innovation or expansion.
Worked on FIORINAL W/CODEINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.